Marker Therapeutics, Inc.

News

Marker Therapeutics: Phenomenal Data In Lymphoma And Other Indications, Yet Little Recognition From The Street

DLBCL data was particularly impressive. Patients who were third and fourth line refractory and relapsed post-transplant are experiencing durable and long responses with some now five years in remission.

Read More

Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019

Marker Therapeutics announces updated data from four clinical trials using the Company’s multi-antigen targeted T cell (MultiTAA) therapies.

Read More

Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon), on Receiving the ASBMT Lifetime Achievement Award

Marker Therapeutics would like to congratulate Scientific Advisory Board Member, Helen E. Heslop, MD, DSc (Hon), on receiving the ASBMT Lifetime Achievement Award.

Read More

Marker Therapeutics to Present at the CAR-TCR Summit Europe

President and CEO, Peter L. Hoang, and Chief Development Officer, Dr. Juan Vera, will be presenting at the CAR-TCR Summit Europe.

Read More

Marker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility

Marker Therapeutics has formally relocated their corporate headquarters from Jacksonville, Florida to Houston, Texas. In addition, the Company has announced that it is now a resident company at Johnson & Johnson Innovation – JLABS (JLABS at TMC).

Read More

Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development

Marker Therapeutics appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development. In this role, she will be responsible for clinical development strategy, clinical study design, and medical oversight of the Company’s therapeutic product candidates. Dr. Koneru joins Marker Therapeutics from Eli Lilly and Company, where she served most recently as Associate Vice President of Immuno-Oncology.

Read More

Marker Therapeutics to Present at the 2019 BIO CEO & Investor Conference

Chief Financial Officer, Anthony H. Kim, to present a corporate overview at the upcoming BIO CEO & Investor Conference on Monday, February 11, 2019.

Read More

Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019

Peter L. Hoang to present a corporate overview at the upcoming Phacilitate Leaders World & World Stem Cell Summit 2019 on January 23, 2019.

Read More

The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019

Data from four abstracts—including three oral presentations—were accepted for presentation at the Transplantation & Cellular Therapy (TCT) Meetings of the American Society for Blood and Marrow Transplantation and the Center for International Blood and Marrow Transplant Research 2019.

Read More

Cancer-Focused Marker Therapeutics Shares Rise After Update on Clinical Trial Pipeline

The Houston, Texas-based immuno-oncology group gave an update on five clinical trials.

Read More